Press "Enter" to skip to content

HALIX Is Expanding Its Protein Production at New cGMP Facility

HALIX, a Dutch contract growth, and manufacturing group (CDMO) centered on scientific and industrial proteins and viral products, has marked the interim completion of a brand new cGMP facility that can focus on creating and producing biopharmaceutical drug substances.

The new 6,700 m2 (72,118-sq.-foot) cGMP facility is situated inside Leiden Bio Science Park, which houses the widest variety of bioscience begin-ups within the Netherlands amongst its 103 devoted medical life sciences corporations and establishments, which embrace Leiden University and Leiden University Medical Center (LUMC).

Building on the cGMP facility started in July 2018. HALIX has mentioned it plans to increase its scope of companies for therapeutic proteins and viral vaccines. The corporate focus on GMP manufacturing of biologics, by manufacturing drug substance on eucaryotic cells, and by performing aseptic fill and end and lyophilization providers.

Full-scale operational manufacturing on the new facility will start within the fourth quarter, HALIX added. The five-degree manufacturing facility comprises a producing line for viral vaccines and viral vectors, and a separate protein manufacturing space with a capacity as much as 1,000 L single-use bioreactors. Lab space can be out there for the course of improvement, analytical improvement, and high-quality management.

All cleanroom areas have a unidirectional course of circulation and are designed to permit business manufacturing of biopharmaceuticals merchandise, in line with HALIX. The price of the power has not been disclosed.

Based in Leiden, the Netherlands, HALIX was based in 2012 and is a 100% owned subsidiary of HAL Allergy Group. Each corporation are owned by Droege Group, a family-owned funding agency specializing in long-term, fairness-financed direct investments in medium-sized corporations or company subsidiaries as a majority shareholder. HALIX says it affords its shoppers end-to-end drug growth companies from the beginning of economic manufacturing after profitable registration of products.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *